Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma

NCT05020392 · clinicaltrials.gov ↗
PHASE3
Phase
UNKNOWN
Status
24
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Collaborators